Forty Seven Inc. to Present New Preclinical Data on 5F9 at the 60th American Society of Hematology (ASH) Annual Meeting
November 01, 2018 09:00 ET
|
Forty Seven, Inc.
-- 5F9 Priming Dose Results in CD47 Pruning, Removing CD47 from Surface of Red Blood Cells to Mitigate Risk of Anemia -- -- 5F9 Demonstrates Synergy in Combination with Azacitidine in Acute Myeloid...
Forty Seven Inc. Announces Publication in The New England Journal of Medicine of 5F9 Phase 1b Clinical Data in Non-Hodgkin’s Lymphoma (NHL)
October 31, 2018 17:00 ET
|
Forty Seven, Inc.
Publication Reaffirms Therapeutic Potential of CD47 Inhibition as Novel Approach to Treating Cancer Enrollment Ongoing in Phase 2 Portion of Clinical Trial Evaluating 5F9 in Combination with...
Forty Seven Inc. Appoints Leading Experts in Immuno-Oncology to its Scientific Advisory Board (SAB)
October 03, 2018 08:00 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV) today announced the formation of its Scientific Advisory Board (SAB), comprised of four leading scientists in the...
Forty Seven Inc. to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
September 06, 2018 08:00 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
Forty Seven Inc. Reports Second Quarter 2018 Financial Results and Recent Business Highlights
August 13, 2018 16:01 ET
|
Forty Seven, Inc.
-- Presented Preliminary Data from Three Clinical Trials of 5F9 as a Monotherapy and Combination Agent ---- Granted Fast Track Designation from the U.S. Food and Drug Administration for 5F9 in Diffuse...
Forty Seven Inc. to Present at the 38th Annual Canaccord Genuity Growth Conference
August 02, 2018 08:00 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
Forty Seven Prices Initial Public Offering
June 27, 2018 21:56 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., June 27, 2018 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical stage immuno-oncology company, announced today the pricing of its initial public offering of...